Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC

Phase 1 Completed 39 enrolled Canadian Cancer Trials Group AstraZeneca · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This research is being done because further research on selumetinib in combination with standard chemotherapy treatment is needed. Although the number of treatment options for patients with advanced non-small cell lung cancer has increased over the past decade, prognosis remains poor, and there is a need for additional therapeutic options.

Timeline

Start: 2013-06-04
Primary completion: 2017-04-18
Completion: 2019-04-02

Publications

Results Goffin JR, Nicholas G, Mates M, Tu D, Chen E, Laurie SA, Juergens R, Robinson A, Goss G, Reaume M, Sun S, Christink K, Maize C, MacFarlan S, Sun X, Ritter H, Seymour L, Bradbury PA. Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. Invest New Drugs. 2019 Jun;37(3):498-506. doi: 10.1007/s10637-018-0680-z. Epub 2018 Oct 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Selumetinib	Small molecule	50 mg	—
Subject	Selumetinib	Small molecule	75 mg	—
Background	Carboplatin	Small molecule	6 unknown	—
Background	Cisplatin	Other / unclassified	75 mg/m2	—
Background	Paclitaxel	Small molecule	200 mg/m2	—
Background	Pemetrexed	Small molecule	500 mg/m2	—

Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC

Summary

Timeline

Publications

Drugs

Indications